NanoViricides Shows Oral Delivery and Anavex Benefits as Field of AD Drugs Narrows
I have truly astounding news from NanoViricides (OTCBB: NNVC). First, however, allow me to respond to a friend who told me recently that I should have reminded my readers that I had predicted the failure of bapineuzumab, the Alzheimer's drug candidate jointly funded by Pfizer, Johnson & Johnson and Elan.
So for the record, I told you so.
In fact, the reason I got this right was that I listened to Dr. Cameron Durrant, formerly a top executive for several Big Pharma companies and Anavex Life Sciences Corp. (OTCBB: AVXL). Durrant knows the inside story when it comes to AD as well as the pharmaceutical industry.
You Must Be A Subscriber To View This Content.
If you are already a subscriber, click the login button below to get access. Not yet a subscriber? Checkout our publication below and get access today!
Breakthrough Technology Alert
This is the best time to be investing in world-changing technologies, as unprecedented innovations are taking off right now… Breakthrough Technology Alert tirelessly researches these exciting new breakthrough technologies to keep you well informed, outline specific opportunities, and keep you ahead of the game.